Abstract
A fundamental characteristic of glioblastomas is heterogeneity at the cellular and molecular levels between tumors as well as between individual cells within the tumor microenvironment. These inter-tumoral and intra-tumoral heterogeneities are what make glioblastomas so difficult to treat in patients. As the tumor progresses over time, it accumulates more alterations and co-opts normal physiological processes for growth and proliferation as well as evasion from the immune system. Tumor Treating Fields (TTFields), as delivered by the Optune device, interferes with the co-opted cell division machinery and potentiates anti-tumor immune response. The pre-specified interim analysis of the EF-14 randomized trial using the device in newly diagnosed glioblastoma patients was positive, and it has shown prolongation of both progression free survival and overall survival in patients received TTFields together with maintenance temozolomide when compared to those treated with temozolomide alone. The median progression free survival was 7.1 (95 % CI 5.9–8.2) months in the TTFields plus temozolomide cohort and 4.0 (95 % CI 3.3–5.2) months in the temozolomide alone cohort (hazard ratio = 0.62 [95 % CI 0.43–0.89], p = 0.001). The overall survival of the intent-to-treat population showed a median overall survival of 19.6 (95 % CI 16.6–24.4) months in the TTFields plus temozolomide group versus 16.6 (95 % CI 13.6–19.2) months in the temozolomide alone group (hazard ratio = 0.74, [95 % CI 0.56–0.98], p = 0.03). The combined treatment was well-tolerated and without unexpected side effects. Although results from additional outcome analyses will likely be reported in the future, the positive data from the interim analysis suggest that TTFields offer benefit to newly diagnosed patients with glioblastoma.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–77.
Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110.
Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011;20:810–7.
Sottoriva A, Spiteri I, Piccirillo SGM, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013;110:4009–14.
Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343:189–93.
Wong ET. Tumor growth, invasion, and angiogenesis in malignant gliomas. J Neurooncol. 2006;77:295–6.
Romero FJ, Ortega A, Titus F, Ibarra B, Navarro C, Rovira M. Gliomatosis cerebri with formation of a glioblastoma multiforme. Study and follow-up by magnetic resonance and computed tomography. J Comput Tomogr. 1988;12:253–7.
Showalter TN, Andrel J, Andrews DW, Curran Jr WJ, Daskalakis C, Werner-Wasik M. Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys. 2007;69:820–4.
Lun M, Lok E, Gautam S, Wu E, Wong ET. The natural history of extracranial metastasis from glioblastoma multiforme. J Neurooncol. 2011;105:261–73.
Müller C, Holtschmidt J, Auer M, Heitzer E, Lamszus E, Schulte A, et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014;6:247ra101.
Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005;23:357–61.
Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, et al. A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients. Clin Cancer Res. 2015;21:3610–8.
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699–708.
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishkawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709–22.
Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2006;13:84–8.
Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19:3165–75.
Wong ET, Lok E, Gautam S, Swanson KD. Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. Br J Cancer. 2015;113:232–41.
Hughes MA, Parisi M, Grossman SA, Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys. 2005;62:1423–6.
Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, et al. Corticosteroids compromise survival in glioblastoma. Brain. 2016;139:1458–71.
Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17:5473–80.
Back MF, Ang EL, Ng WH, See SJ, Lim CC, Chan SP, et al. Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy. Ann Acad Med Singapore. 2007;36:338–42.
Takano S, Kimu H, Tsuda K, Osuka S, Nakai K, Yamamoto T, et al. Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab. Acta Neurochir Suppl. 2013;118:185–9.
Chu K, Jeong SW, Jung KH, Han SY, Lee ST, Kim M, et al. Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. J Cereb Blood Flow Metab. 2004;24:926–33.
Lee SH, Park HK, Ryu WS, Lee JS, Bae HJ, Han MK, et al. Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: a multicenter randomized controlled trial. Eur J Neurol. 2013;20:1161–9.
Carpentier AF, Ferrari D, Bailon O, Ursu R, Banissi C, Dubessy AL, et al. Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients. Eur J Neurol. 2012;19:1337–42.
Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64:3288–95.
Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One. 2015;10:e0125269.
Lee SX, Wong E, Swanson K. Disruption of cell division within anaphase by tumor treating electric fields (TTFields) leads to immunogenic cell death. Neuro-Oncology. 2013;15 Suppl 3:iii66–7.
Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomized phase III trial of a novel treatment modality. Eur J Cancer. 2012;48:2192–202.
Rulseh AM, Keller J, Klener J, Sroubek J, Dbalý V, Syrucek M, et al. Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields. World J Surg Oncol. 2012;10:220.
Kirson ED, Schneiderman RS, Dbalý V, Tovaryš F, Vymazal J, Itzhaki A, et al. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys. 2009;9:1.
Macdonald DR, Casino TL, Schold Jr SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–80.
Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma. A randomized clinical trial. JAMA. 2015;314:2535–43.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Wong, E.T., Ram, Z. (2016). Tumor Treating Fields Therapy for Newly Diagnosed Glioblastoma. In: Wong, E. (eds) Alternating Electric Fields Therapy in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-30576-9_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-30576-9_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-30574-5
Online ISBN: 978-3-319-30576-9
eBook Packages: MedicineMedicine (R0)